Okta reports second-quarter revenue of $728 million, beating analyst estimates of $712.01 million, according to Benzinga Pro.
Lutnick says the Trump administration is considering buying ownership stakes in major defense contractors.
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.
BEEM shares rise as U.S. General Services Administration renews contract through 2030, with options for 2040.
Lululemon stock dipped as investors weighed North America weakness, tariff headwinds, and discounting risks against its brand strength and global growth.
RTX shares rose after Pratt & Whitney secured a $2.8B Pentagon contract to produce F135 engines for the F-35 program.
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.
CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market.